HN2005000255A - Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis - Google Patents

Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis

Info

Publication number
HN2005000255A
HN2005000255A HN2005000255A HN2005000255A HN2005000255A HN 2005000255 A HN2005000255 A HN 2005000255A HN 2005000255 A HN2005000255 A HN 2005000255A HN 2005000255 A HN2005000255 A HN 2005000255A HN 2005000255 A HN2005000255 A HN 2005000255A
Authority
HN
Honduras
Prior art keywords
pirrolotriazine
angiogenesis
derivatives
diseases associated
proliferative disorders
Prior art date
Application number
HN2005000255A
Other languages
English (en)
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2005000255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HN2005000255A publication Critical patent/HN2005000255A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTA INVENCION SE REFIERE A NUEVOS COMPUESTOS DE PIRROLOTRIAZINA, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS Y EL USO DE ESOS COMPUESTOS Y COMPOSICIONES PARA LA PREVENCION Y/O TRATMIENTO DE TRASTORNOS HIPER-PROLIFERATIVOS Y ENFERMEDADES ASOCIADAS CON LA ANGIOGENESIS.
HN2005000255A 2004-06-03 2005-06-01 Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis HN2005000255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
HN2005000255A true HN2005000255A (es) 2010-09-17

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2005000255A HN2005000255A (es) 2004-06-03 2005-06-01 Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis

Country Status (31)

Country Link
US (3) US7563791B2 (es)
EP (1) EP1765823B1 (es)
JP (1) JP4958772B2 (es)
KR (1) KR101235602B1 (es)
CN (1) CN1993361B (es)
AR (1) AR049138A1 (es)
AT (1) ATE462708T1 (es)
AU (1) AU2005252217B2 (es)
BR (1) BRPI0510848A (es)
CA (1) CA2569396C (es)
DE (1) DE602005020293D1 (es)
EC (1) ECSP067043A (es)
ES (1) ES2342722T3 (es)
GT (1) GT200500137A (es)
HK (1) HK1109141A1 (es)
HN (1) HN2005000255A (es)
IL (1) IL179264A0 (es)
MA (1) MA28689B1 (es)
MX (1) MX279139B (es)
MY (1) MY145077A (es)
NO (1) NO20070049L (es)
NZ (1) NZ551742A (es)
PE (1) PE20060243A1 (es)
PH (1) PH12006502386B1 (es)
RU (1) RU2401269C2 (es)
SG (1) SG127661A1 (es)
SV (1) SV2006002134A (es)
TW (1) TW200608979A (es)
UY (1) UY28931A1 (es)
WO (1) WO2005121147A1 (es)
ZA (1) ZA200700011B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
JP5249776B2 (ja) 2005-12-02 2013-07-31 バイエル・ヘルスケア・エルエルシー 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体
EP1976847B1 (en) 2005-12-21 2015-06-17 Novartis AG Pyrimidinyl aryl urea derivatives being fgf inhibitors
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
CA2698795C (en) 2007-09-10 2016-04-19 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
MX2010003269A (es) * 2007-09-25 2010-08-02 Bayer Healthcare Llc Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
CA2877474A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
ES2570862T3 (es) 2011-12-15 2016-05-20 Bayer Ip Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas en el tratamiento de cáncer
CN104136439B (zh) * 2012-02-23 2017-01-18 拜耳知识产权有限责任公司 取代的苯并噻吩基‑吡咯并三嗪及其用途
PE20170303A1 (es) * 2014-06-17 2017-04-19 Chiesi Farm Spa Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US20170252350A1 (en) 2016-03-03 2017-09-07 Cornell University Small molecule ire1-alpha inhibitors
LT3436461T (lt) * 2016-03-28 2024-03-12 Incyte Corporation Pirolotriazino junginiai kaip tam inhibitoriai
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
KR20210049088A (ko) 2018-06-29 2021-05-04 인사이트 코포레이션 Axl/mer 억제제의 제형
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
PE20220573A1 (es) * 2019-05-13 2022-04-20 Relay Therapeutics Inc Inhibidores de fgfr y metodos de uso de los mismos
KR20220062366A (ko) * 2019-09-26 2022-05-16 센젠 타겟알엑스, 아이엔씨. 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도
EP4180433A1 (en) * 2020-07-10 2023-05-17 Beijing Findcure Biosciences, Ltd. Triazine compound and composition and use thereof
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1183033T3 (da) * 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
NZ525334A (en) * 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5249776B2 (ja) 2005-12-02 2013-07-31 バイエル・ヘルスケア・エルエルシー 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX2010003269A (es) 2007-09-25 2010-08-02 Bayer Healthcare Llc Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.

Also Published As

Publication number Publication date
AU2005252217A1 (en) 2005-12-22
UY28931A1 (es) 2005-12-30
AR049138A1 (es) 2006-06-28
CA2569396C (en) 2011-12-20
EP1765823B1 (en) 2010-03-31
NO20070049L (no) 2007-01-30
MA28689B1 (fr) 2007-06-01
AU2005252217B2 (en) 2011-05-12
JP4958772B2 (ja) 2012-06-20
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25
ATE462708T1 (de) 2010-04-15
US20130225809A1 (en) 2013-08-29
CN1993361B (zh) 2010-05-26
KR20070035028A (ko) 2007-03-29
PE20060243A1 (es) 2006-04-21
MXPA06013457A (es) 2007-03-01
SV2006002134A (es) 2006-10-04
ECSP067043A (es) 2006-12-29
MY145077A (en) 2011-12-15
EP1765823A1 (en) 2007-03-28
TW200608979A (en) 2006-03-16
NZ551742A (en) 2010-08-27
ZA200700011B (en) 2008-11-26
GT200500137A (es) 2006-05-18
US7563791B2 (en) 2009-07-21
US8338595B2 (en) 2012-12-25
CN1993361A (zh) 2007-07-04
PH12006502386B1 (en) 2010-12-23
DE602005020293D1 (de) 2010-05-12
KR101235602B1 (ko) 2013-02-21
ES2342722T3 (es) 2010-07-13
IL179264A0 (en) 2007-03-08
HK1109141A1 (en) 2008-05-30
BRPI0510848A (pt) 2007-11-27
US20070208013A1 (en) 2007-09-06
JP2008501703A (ja) 2008-01-24
WO2005121147A1 (en) 2005-12-22
SG127661A1 (en) 2007-01-30
MX279139B (es) 2010-09-21
RU2401269C2 (ru) 2010-10-10
CA2569396A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
BRPI0511527A (pt) compostos e composições como moduladores de ppar
WO2007089557A3 (en) Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
TW200602330A (en) Compounds and compositions as PPAR modulators
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
BRPI0510024A (pt) compostos e composições como modulares de ppar
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CR9953A (es) Diarilurea para el tratamiento de hipertension pulmonar
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.